antitubercular

Pyrazinamide (Pyrazinecarboxamide), an antimycobacterial, is utilized therapeutically as an antitubercular agent, which is a synthetic pyrazinoic acid amide derivative.

Antitubercular agent-41 is a antibacterial agent.

Antitubercular agent-30 has antitubercular activity.

Antitubercular agent-36 (compound 53) is an effective inhibitor of Mycobacterium tuberculosis H37Rv, with a minimum inhibitory concentration (MIC90) of 1.25 μg mL, and is utilized in tuberculosis research [1].

Antitubercular agent-31 is an antitubercular agent that inhibits M. tuberculosisH37Rv (MIC: 0.03 μM) and also inhibits DprE1 (IC50: 1.1 μM).

Antitubercular agent-39 (Compound P1) is a potent agent effective against both drug-resistant and drug-susceptible clinical isolates of tuberculosis, inhibiting the Mtb strain H37Rv with a minimum inhibitory concentration (MIC) of less than 1 μM [1].

Antitubercular agent-29 (compound 6xa) is a potent Mycobacterium tuberculosis (Mtb) inhibitor, effective against drug-resistant (DR) and drug-susceptible (DS) strains with a minimum inhibitory concentration (MIC) of 0.03 μg mL for DS-Mtb and 0.03-0.06 μg mL for DR-Mtb strains, and demonstrates favorable selectivity (SI>40) against Vero cells.

Antitubercular agent-10 exhibits potent antitubercular activity with a MIC value of 30 nM.

Antitubercular agent-9 exhibits potent activity against tuberculosis, demonstrating a minimum inhibitory concentration (MIC) range of 1.03-2.32 μM.

Antitubercular agent 34 (compound 42g) effectively inhibits Mtb H37Rv growth with a MIC 90 value of 1.25 µg mL and demonstrates resistance to metabolic degradation by human liver microsomes, indicating its potential for tuberculosis research [1].

Antitubercular agent-19 is an antitubercular agent. antitubercular agent-19 showed good antitubercular effects against MTB H37Rv and MDR-MTB (MIC <0.016 μg ml). antitubercular agent-19 showed low cytotoxicity and relatively high acute lethality in BALB c mice. Antitubercular agent-19 exhibited low cytotoxicity and relatively high acute lethal toxicity in BALB c mice.

Antitubercular Agent-37 exhibits antimycobacterial properties and functions as an antibacterial agent with an MIC (minimum inhibitory concentration) value of 0.16 μg mL, making it suitable for tuberculosis research [1].

Antitubercular agent-17 (Compound 8a) is an efficacious antitubercular agent, demonstrating Minimum Inhibitory Concentration (MIC) values of 2 μg ml against M. tuberculosis H37Rv, Spec. 192, and Spec. 210, and 128 μg ml against Spec. 800. It exhibits highly selective antimycobacterial effects [1].

Antitubercular agent-12 (Compound 2c) is a highly effective antitubercular agent with a MIC (Minimum Inhibitory Concentration) value of 1.439 μg mL and significantly reduced cytotoxicity, evidenced by a CC50 (50% Cytotoxic Concentration) value of 57.34 μg mL [1].

Antitubercular agent-23 is an effective anti-Candida and anti-tuberculosis agent against Candida albicans MTCC 3017 (MIC: 1.1 μg ml) and M. tuberculosis (H37Rv) (MIC: 1 μg ml).

Antitubercular agent-32 is a Benzothiazinone derivative that inhibits Mycobacterium tuberculosis and exhibits good metabolic stability and water solubility. Antitubercular agent-32 can act on decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1, IC50: 3.9 μM) and exhibits antitubercular effects.

Antitubercular agent-14 (Compound 1) exhibits antitubercular activity with an MIC value of 0.3 μg mL against M. tuberculosis [1].

Antitubercular agent-18 (Compound 9a) is an antitubercular agent that exhibits highly selective antimycobacterial effects, with minimum inhibitory concentration (MIC) values of 2 μg ml against M. tuberculosis H37Rv, Spec. 192, and Spec. 210, and 128 μg ml against Spec. 800, demonstrating its efficacy in inhibiting the growth of these mycobacterial strains [1].

Antitubercular Agent-38, a derivative of Benzothiazinones (BTZs), demonstrates potent antituberculosis activity while maintaining low cardiac toxicity and minimal cell cytotoxicity [1]. This orally active compound is a promising therapeutic in the treatment of tuberculosis.

Antitubercular agent-16 (Compound 5q) is a potent antitubercular agent exhibiting high efficacy against various strains of M. tuberculosis, including H37Rv, CF16, CF61, CF76, CF152, and CF161, with MIC 90 values ranging from 0.40 to 23.51 μg mL. Notably, Antitubercular agent-16 demonstrates minimal cytotoxicity towards macrophages and pulmonary fibroblasts, further highlighting its potential as a therapeutic agent [1].

Antitubercular agent-21 (Compound 15) is an antitubercular agent with low cytotoxicity, exhibiting an MIC of 0.4 μg mL against M. tuberculosis H37Rv. However, it shows lower activity against other microorganisms, including gram-positive bacteria, gram-negative bacteria, and fungi [1].

Antitubercular agent-25 (Compound 28) is an anti-tubercular agent with an extracellular IC50 of 0.42 μM and an intracellular IC50 of 0.20 μM against M. tuberculosis H37Rv, and it demonstrates good metabolic stability.

Antitubercular agent-27 (compound 1) exhibits potent antitubercular properties with an IC50 of 3.2 μM, an MIC of 7.8 μM, and an IC90 of 7.0 μM, effectively targeting resistant Mycobacterium tuberculosis H37Rv isolates and displaying significant intracellular antimycobacterial activity with low cytotoxicity [1].

Antitubercular agent-13 (Compound 3d) is an antitubercular compound with MIC values of 0.007 μg mL against MTB H37Rv and 1.851 μg mL against MDR-MTB 16833, respectively, and exhibits metabolic instability [1].